• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 7
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue7

In-Vitro Antioxidant And Anticancer Evaluation Of Newly Synthesized N-(5-Oxo-2-Phenylimidazolidin-1-Yl)-4-(3,4-Dihydroxyphenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxamide

    S. Shanmugam K. Neelakandan M. Gopalakrishnan S. Pazhamalai

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 353-370

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

A novel N-(5-oxo-2-phenylimidazolidin-1-yl)-4-(3,4-dihydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1) was synthesized using Biginelli reaction at room temperature. The dual heterocyclic compound 1 was characterized using the analytical techniques such as FT-IR, 1H & 13C-NMR, Mass analysis, UV-visible and fluorescent spectroscopic system. The data on charge density was used to explain the characteristics of molecular systems. In addition, in the form of the complete and partial density of states, the HOMO-LUMO energy gap, electrostatic potential map and some quantum chemical insights have been obtained. Furthermore, to demonstrate the possible applications of dihydropyrimidinone 1 in nonlinear optics the polarizability and first hyperpolarizability were measured. Molecular docking is also determined in order to illustrate the overexpression of estrogen receptor in 80 % of 2J9M protein. The compound 1 was subjected for its antioxidant (ABTS) and anticancer activity (DPPH) by in-vitro analyses and found with substantial antioxidant activity.
Keywords:
    Biginelli reaction Dihydropyrimidinone anticancer antioxidant DPPH & ABTS method HOMO-LUMO and NLO
  • PDF (1476 K)
  • XML
(2020). In-Vitro Antioxidant And Anticancer Evaluation Of Newly Synthesized N-(5-Oxo-2-Phenylimidazolidin-1-Yl)-4-(3,4-Dihydroxyphenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxamide. European Journal of Molecular & Clinical Medicine, 7(7), 353-370.
S. Shanmugam; K. Neelakandan; M. Gopalakrishnan; S. Pazhamalai. "In-Vitro Antioxidant And Anticancer Evaluation Of Newly Synthesized N-(5-Oxo-2-Phenylimidazolidin-1-Yl)-4-(3,4-Dihydroxyphenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxamide". European Journal of Molecular & Clinical Medicine, 7, 7, 2020, 353-370.
(2020). 'In-Vitro Antioxidant And Anticancer Evaluation Of Newly Synthesized N-(5-Oxo-2-Phenylimidazolidin-1-Yl)-4-(3,4-Dihydroxyphenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxamide', European Journal of Molecular & Clinical Medicine, 7(7), pp. 353-370.
In-Vitro Antioxidant And Anticancer Evaluation Of Newly Synthesized N-(5-Oxo-2-Phenylimidazolidin-1-Yl)-4-(3,4-Dihydroxyphenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxamide. European Journal of Molecular & Clinical Medicine, 2020; 7(7): 353-370.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 220
  • PDF Download: 381
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus